Workflow
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
Kymera TherapeuticsKymera Therapeutics(US:KYMR) ZACKSยท2025-06-03 16:16

Core Insights - Kymera Therapeutics, Inc. (KYMR) announced positive clinical results from the phase I study of investigational candidate KT-621, leading to a surge in shares as data exceeded expectations and showed comparable efficacy to Dupixent [2][3][9] Company Overview - KT-621 is a first-in-class, once daily, oral degrader of STAT6, targeting IL-4/IL-13 signaling and Th2 inflammation [2][9] - The phase I study was a double-blind, placebo-controlled trial with 118 subjects, focusing on safety and tolerability of KT-621 [5][9] Clinical Results - KT-621 demonstrated a favorable plasma pharmacokinetic profile, achieving steady-state by day four and showing significant STAT6 degradation in blood and skin [6][7] - A mean STAT6 degradation of over 90% was observed at doses above 1.5 mg, with complete degradation at doses greater than 50 mg [7][9] - The candidate showed a placebo-like safety profile with no serious adverse events reported [10][9] Future Development - Kymera initiated the KT-621 BroADen phase Ib study in April 2025, with data expected in Q4 2025, and plans to start two phase IIb studies in Q4 2025 and Q1 2026 [11][12] - The company aims to accelerate KT-621's development for multiple Th2 indications [12][13] Financial Position - As of March 31, 2025, Kymera had $775 million in cash and equivalents, providing a cash runway into the first half of 2028 [15]